The device is approved for use in dental bone and tissue regeneration procedures. Credit: Marek Studzinski / Unsplash.

Australian regenerative medicine company Orthocell has received US 510k clearance to market and supply its collagen medical device, Striate+, in the country.

The device is approved for use in dental bone and tissue regeneration procedures such as dental bone defect repair, augmentation around dental implants in immediate and delayed extraction sockets, and guided tissue regeneration processes in intrabony periodontal defects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The clearance enables Orthocell to deliver Striate+ in the US dental bone and tissue regeneration market.

Furthermore, the company will negotiate with global dental companies for US marketing and distribution rights while retaining the manufacturing of the finished product.

Orthocell MD Paul Anderson said: “US approval is a significant inflection point for our company and we are now primed to partner and distribute this product.

“I look forward to working with our leading dental surgeons to introduce the new global brand, Striate+, previously branded as CelGro dental, to make a meaningful impact in the US market.”

The latest development follows the company’s application submitted to the Food and Drug Administration (FDA) last May.

US dental surgeon Dr Pamela Ray said: “Striate+ has exceptional handling qualities – when manipulating, it remains dimensionally stable and unrolls easily back to the original size.

“It has great tensile strength and does not deform when hydrated.”

According to the surgeon feedback, Striate+ has various benefits and could help surgeons to offer enhanced patient outcomes through optimal handling characteristics, tissue integration qualities, and improved bone healing.

In 2017, Orthocell obtained CE-Mark for its CelGro medical device, enabling marketing within the EU countries.